Myriad Genetics expanded availability and clinical evidence for its ultrasensitive Precise MRD test, moving beyond an early access breast-cancer program. The company is broadening indications to colorectal and renal cancers and is preparing to generate additional evidence for clinical adoption, anchored by data from the multicenter MONITOR-Breast study in Future Oncology. The test’s workflow—tumor-informed whole-genome sequencing tracking of up to 1,000 variants—targets ultra-low residual disease detection intended to support treatment response assessment and post-therapy surveillance decisions.